EMB vs. MRNA
EMB (iShares J.P. Morgan USD Emerging Markets Bond ETF) is Emerging Markets Bonds fund tracking the JPMorgan EMBI Global Core Index, while MRNA (Moderna, Inc.) is a stock. Over the past 5 years, EMB returned 1.79%/yr vs -25.59%/yr for MRNA. At a 0.21 correlation, their price movements are largely independent.
Performance
EMB vs. MRNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, EMB achieves a 2.29% return, which is significantly lower than MRNA's 69.24% return.
EMB
- 1D
- 0.09%
- 1M
- 1.29%
- YTD
- 2.29%
- 6M
- 2.72%
- 1Y
- 11.53%
- 3Y*
- 9.63%
- 5Y*
- 1.79%
- 10Y*
- 3.39%
MRNA
- 1D
- 0.54%
- 1M
- -0.24%
- YTD
- 69.24%
- 6M
- 69.42%
- 1Y
- 87.14%
- 3Y*
- -26.94%
- 5Y*
- -25.59%
- 10Y*
- —
EMB vs. MRNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
EMB iShares J.P. Morgan USD Emerging Markets Bond ETF | 2.29% | 13.85% | 5.54% | 10.62% | -18.63% | -2.23% | 5.42% | 15.48% | 1.19% |
MRNA Moderna, Inc. | 69.24% | -29.08% | -58.19% | -44.63% | -29.28% | 143.11% | 434.10% | 28.09% | -30.59% |
Correlation
The correlation between EMB and MRNA is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.35 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.31 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Dec 7, 2018 | 0.21 |
The correlation between EMB and MRNA shifts across timeframes, from 0.21 (all time) to 0.35 (1 year), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
EMB vs. MRNA — Risk / Return Rank
EMB
MRNA
EMB vs. MRNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares J.P. Morgan USD Emerging Markets Bond ETF (EMB) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| EMB | MRNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.64 | ||
| Sortino ratioReturn per unit of downside risk | +0.69 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.24 | +0.13 |
| Calmar ratioReturn relative to maximum drawdown | 2.41 | 2.34 | +0.08 |
| Martin ratioReturn relative to average drawdown | 10.28 | 4.59 | +5.69 |
Loading charts...
Drawdowns
EMB vs. MRNA - Drawdown Comparison
The maximum EMB drawdown since its inception was -34.70%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for EMB and MRNA.
Loading charts...
Drawdown Indicators
| EMB | MRNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -34.70% | -95.38% | +60.68% |
Max Drawdown (1Y)Largest decline over 1 year | -4.51% | -35.51% | +31.00% |
Max Drawdown (3Y)Largest decline over 3 years | -7.95% | -86.58% | +78.63% |
Max Drawdown (5Y)Largest decline over 5 years | -28.74% | -95.38% | +66.64% |
Max Drawdown (10Y)Largest decline over 10 years | -28.74% | — | — |
Current DrawdownCurrent decline from peak | 0.00% | -89.70% | +89.70% |
Average DrawdownAverage peak-to-trough decline | -5.05% | -57.06% | +52.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 1.06% | 18.06% | -17.00% |
Volatility
EMB vs. MRNA - Volatility Comparison
The current volatility for iShares J.P. Morgan USD Emerging Markets Bond ETF (EMB) is 2.02%, while Moderna, Inc. (MRNA) has a volatility of 17.56%. This indicates that EMB experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| EMB | MRNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 2.02% | 17.56% | -15.54% |
Volatility (6M)Calculated over the trailing 6-month period | 4.66% | 48.82% | -44.16% |
Volatility (1Y)Calculated over the trailing 1-year period | 5.67% | 64.75% | -59.08% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 9.76% | 66.49% | -56.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 9.96% | 72.15% | -62.19% |
Dividends
EMB vs. MRNA - Dividend Comparison
EMB's dividend yield for the trailing twelve months is around 5.03%, while MRNA has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EMB iShares J.P. Morgan USD Emerging Markets Bond ETF | 5.03% | 4.98% | 5.46% | 4.74% | 5.04% | 3.89% | 3.88% | 4.51% | 5.64% | 4.54% | 4.83% | 4.84% |
MRNA Moderna, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
EMB and MRNA have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MRNA has higher volatility (17.56%) compared to EMB (2.02%). In terms of maximum drawdown, EMB dropped -34.70% vs MRNA's -95.38%.
EMB currently has the higher Sharpe Ratio (1.92 vs 1.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for EMB and MRNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer